Form D · Pharmaceuticals
AYTU BIOSCIENCE, INC
Englewood, CO · CIK 0001385818
Offering snapshot reported Oct 31, 2019 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 16, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 31, 2019 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Aug 24, 2017 | Initial | $11,839,995 | No comparison | 70 | SEC filing |
| May 16, 2017 | Initial | $1,750,000 | No comparison | 16 | SEC filing |
| Sep 22, 2015 | Amendment | $5,175,000 | $3,165,000vs Aug 5, 2015 | 96 | SEC filing |
| Aug 5, 2015 | Initial | $2,010,000 | No comparison | 20 | SEC filing |
| Feb 4, 2011 | Initial | $4,000 | No comparison | 1 | SEC filing |
| Jul 22, 2010 | Initial | $10,000 | No comparison | 2 | SEC filing |
| Apr 10, 2009 | Initial | $4,500 | No comparison | Not reported | SEC filing |
| Dec 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $800K
- Finders' fees
- $0
- Form D file number
- 021-352349
Series F Convertible Preferred Stock and Common Stock Purchase Warrants
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ladenburg Thalmann & Co. Inc. | 505 |
Source: Form D, filed Oct 31, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Boyd | Director |
| Gary Cantrell | Director |
| Jarrett Disbrow | Executive |
| Josh Disbrow | Director, Executive |
| Joshua R. Disbrow | Director, Executive |
| Carl Dockery | Director |
| John Donofrio Jr. | Director |
| John A. Donofrio, Jr. | Director |
| Gregory A. Gould | Executive |
| David Green | Executive |
| Michael Macaluso | Director |
| Ketan Mehta | Director |
| James` B Wiegand | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
373 Inverness Parkway Suite 206
Englewood, CO, 80112
Englewood, CO, 80112